Phenotypes Associated with This Genotype

Genotype
MGI:3833891

cn3

• Allelic Composition: Supv3l1^tm2.1Jkl/Supv3l1^tm2.2Jkl; Tg(CAG-cre/Esr1*)5Amc/0
• Genetic Background: involves: 129P2/OlaHsd * 129S4/SvJaeSor * C57BL/6 * FVB/N

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

Thymic atrophy in Supv3l1^tm2.1Jkl/Supv3l1^tm2.2Jkl Tg(CAG-cre/Esr1*)5Amc/0 mice

mortality/aging

premature death ( J:144991 )

• mice die by 15 weeks of age

• tamoxifen-treated mice die by 6 weeks of age

immune system

increased macrophage derived foam cell number ( J:144991 )

• in the lungs in tamoxifen-treated mice

thymus atrophy ( J:144991 )

• mice exhibit thymic atrophy that develops more rapidly in tamoxifen treated mice

thymus hypoplasia ( J:144991 )

• 6-fold in tamoxifen-treated mice compared to mice heterozygous for the floxed allele

abnormal T cell differentiation ( J:144991 )

• tamoxifen-treated mice exhibit decreased DN2, DN3, and DN4 cells compared to mice heterozygous for the floxed allele

decreased double-negative T cell number ( J:144991 )

• in tamoxifen-treated mice

decreased double-positive T cell number ( J:144991 )

• more than 10-fold in tamoxifen-treated mice

decreased CD4-positive, alpha-beta T cell number ( J:144991 )

• in tamoxifen-treated mice

decreased CD8-positive, alpha-beta T cell number ( J:144991 )

• in tamoxifen-treated mice

lung inflammation ( J:144991 )

• chronic and acute in untreated and tamoxifen-treated mice

growth/size/body

decreased body weight ( J:144991 )

• in tamoxifen-treated mice

cachexia ( J:144991 )

adipose tissue

decreased subcutaneous adipose tissue amount ( J:144991 )

• mice exhibit adipose tissue loss that develops more rapidly in tamoxifen treated mice

respiratory system

lung inflammation ( J:144991 )

• chronic and acute in untreated and tamoxifen-treated mice

abnormal lung interstitium morphology ( J:144991 )

• thickened in in tamoxifen-treated mice and untreated mice

muscle

decreased skeletal muscle mass ( J:144991 )

• mice exhibit sarcopenia atrophy that develops more rapidly in tamoxifen treated mice

dystrophic muscle ( J:144991 )

skeleton

kyphosis ( J:144991 )

• mice exhibit kyphosis that develops more rapidly in tamoxifen treated mice

endocrine/exocrine glands

thymus atrophy ( J:144991 )

• mice exhibit thymic atrophy that develops more rapidly in tamoxifen treated mice

thymus hypoplasia ( J:144991 )

• 6-fold in tamoxifen-treated mice compared to mice heterozygous for the floxed allele

decreased sebaceous gland number ( J:144991 )

• in tamoxifen-treated mice, the numbers of sebaceous glands is reduced compared to in untreated mice

cardiovascular system

dilated vasculature ( J:144991 )

• tamoxifen-treated mice exhibit focal vascular ectasia in the skin unlike in untreated mice

• mice treated topically with tamoxifen exhibit dilated vasculature at the site of application

behavior/neurological

abnormal locomotor behavior ( J:144991 )

• locomotor functions fail in moribund mice

digestive/alimentary system

abnormal duodenum morphology ( J:144991 )

• tamoxifen-treated mice exhibit an increase in apoptosis compared to untreated mice

hematopoietic system

increased macrophage derived foam cell number ( J:144991 )

• in the lungs in tamoxifen-treated mice

thymus atrophy ( J:144991 )

• mice exhibit thymic atrophy that develops more rapidly in tamoxifen treated mice

thymus hypoplasia ( J:144991 )

• 6-fold in tamoxifen-treated mice compared to mice heterozygous for the floxed allele

abnormal T cell differentiation ( J:144991 )

• tamoxifen-treated mice exhibit decreased DN2, DN3, and DN4 cells compared to mice heterozygous for the floxed allele

decreased double-negative T cell number ( J:144991 )

• in tamoxifen-treated mice

decreased double-positive T cell number ( J:144991 )

• more than 10-fold in tamoxifen-treated mice

decreased CD4-positive, alpha-beta T cell number ( J:144991 )

• in tamoxifen-treated mice

decreased CD8-positive, alpha-beta T cell number ( J:144991 )

• in tamoxifen-treated mice

cellular

increased macrophage derived foam cell number ( J:144991 )

• in the lungs in tamoxifen-treated mice

integument

integument phenotype ( J:144991 )

N • unlike in Supv3l1^tm2Jkl/Supv3l1^tm2Jkl floxed Tg(Mx1-cre)1Cgn mice, tamoxifen-treated mice exhibit normal hair growth

decreased subcutaneous adipose tissue amount ( J:144991 )

• mice exhibit adipose tissue loss that develops more rapidly in tamoxifen treated mice

decreased sebaceous gland number ( J:144991 )

• in tamoxifen-treated mice, the numbers of sebaceous glands is reduced compared to in untreated mice

abnormal skin morphology ( J:144991 )

• tamoxifen treated mice exhibit focal vascular ectasia, reduced adipose tissue, and atrophic muscle layer in the skin unlike in untreated mice

abnormal dermal layer morphology ( J:144991 )

• apoptosis rates in the basal layer are increased in tamoxifen-treated mice compared to in untreated mice

hyperkeratosis ( J:144991 )

• mild in tamoxifen-treated mice and at the site of application in mice treated topically with tamoxifen

parakeratosis ( J:144991 )

• at the site of tamoxifen application when applied directly to the skin

abnormal epidermis stratum granulosum morphology ( J:144991 )

• hypergranulosis develops in tamoxifen-treated mice and at the site of application in mice treated topically with tamoxifen

acanthosis ( J:144991 )

• in tamoxifen-treated mice

thick epidermis ( J:144991 )

• in tamoxifen-treated mice and at the site of tamoxifen application when applied directly to the skin

reddish skin ( J:144991 )

• at the site of tamoxifen application when applied directly to the skin

scaly skin ( J:144991 )

• on the skin and tails of tamoxifen-treated mice and at the site of tamoxifen application when applied directly to the skin